TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31004814

Group type: EXPERIMENTAL
Intervention: 3–4 weeks postpartum appointment
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: 6–8 weeks postpartum appointment
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Overall study sample
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: 3–4 weeks group
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: 6–8 weeks group
Number of subjects: 364
Study: 29543134

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham training control
Number of subjects: 20
Study: 26593781

Group type: EXPERIMENTAL
Intervention: Advanced sun protection intervention (sunscreen pre-application/reapplication; protective hats and clothing; use of shade)
Number of subjects: 4347

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 4347
Study: 25187755

Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg
Number of subjects: 289

Group type: COMPARATOR
Intervention: Neostigmine 50 μg/kg
Number of subjects: 289
Study: 23106879

Group type: EXPERIMENTAL
Intervention: Bipolar plasma vaporization of the prostate (BPVP)
Number of subjects: 30
Study: 18975258

Group type: EXPERIMENTAL
Intervention: Respiratory Muscle Training (RMT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (no RMT)
Number of subjects: 27
Study: 17180485

Group type: EXPERIMENTAL
Intervention: Milk drink supplemented with whey peptides (125 ml every morning for 12 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control product
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Milk drink supplemented with whey peptides
Number of subjects: 54
Study: 15539863

Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Rupatadine 20 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Rupatadine 40 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Rupatadine 80 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Hydroxyzine 25 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 11241439

Group type: EXPERIMENTAL
Intervention: Conscious Sedation (CS)
Number of subjects: 25

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 25
Study: 9738312

Group type: EXPERIMENTAL
Intervention: Categorized participants under high task or situational uncertainty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Identification with minimal in-group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-esteem as a derivative motive
Number of subjects: 0
Study: 7780297

Group type: EXPERIMENTAL
Intervention: Node-link mapping counseling strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard counseling without node-link mapping
Number of subjects: 0
Study: 3169959

Group type: EXPERIMENTAL
Intervention: 200 mg of zinc sulphate orally thrice a day for one month
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31704093

Group type: EXPERIMENTAL
Intervention: Increased compression factor (ICF, 1.75 D)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional compression factor (CCF, 0.75 D)
Number of subjects: 25
Study: 31015581

Group type: EXPERIMENTAL
Intervention: Most productive fields
Number of subjects: 350

Group type: COMPARATOR
Intervention: Least productive fields
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Soil type and crop type
Number of subjects: 350
Study: 28150976

Group type: EXPERIMENTAL
Intervention: Yes/No questions about clothing placement
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Forced-choice questions about clothing placement
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Open-choice questions about clothing placement
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Where questions about clothing placement
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Task using stickers and boxes
Number of subjects: 97
Study: 25864752

Group type: EXPERIMENTAL
Intervention: Persimmon leaf extract
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ginkgo biloba extract
Number of subjects: 60
Study: 23332667

Group type: EXPERIMENTAL
Intervention: Low birth weight (LBW) group
Number of subjects: 46

Group type: COMPARATOR
Intervention: Normal birth weight (NBW) group
Number of subjects: 46
Study: 21478756

Group type: EXPERIMENTAL
Intervention: Rabeprazole 0.14 mg/kg (part 1)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Rabeprazole 0.5 mg/kg (part 2)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Rabeprazole 1 mg/kg (part 2)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Rabeprazole (0.14 mg/kg, 0.5 mg/kg, 1 mg/kg)
Number of subjects: 28
Study: 19646017

Group type: EXPERIMENTAL
Intervention: 5‐Fr silicon drain with an internal lumen and side holes (intraluminal stent group)
Number of subjects: 21

Group type: COMPARATOR
Intervention: 10‐Fr silicon drain with channels along the sides (channel stent group)
Number of subjects: 21
Study: 18257356

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 15560155

Group type: EXPERIMENTAL
Intervention: Permixon (320 mg/day for 3, 6, and 12 months)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no permixon)
Number of subjects: 49
Study: 11119183

Group type: EXPERIMENTAL
Intervention: QI-meds
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: QI-therapy
Number of subjects: 181

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 181
Study: 9070519

Group type: EXPERIMENTAL
Intervention: Desirudin (Revasc, CGP 39393); 15 mg two times a day, administered subcutaneously for 8-11 days.
Number of subjects: 445

Group type: COMPARATOR
Intervention: Unfractionated heparin; 5000 international units three times a day, administered subcutaneously for 8-11 days.
Number of subjects: 445
Study: 8379169

Group type: EXPERIMENTAL
Intervention: Cocktail-group received 100 ml of a homogenous fluorescein dilution
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fraction-group received 45 ml of unstained solution followed by 10 ml of concentrated dye
Number of subjects: 10
Study: 3723496

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg TID
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 29519156

Group type: EXPERIMENTAL
Intervention: Attentional-training
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control
Number of subjects: 3
Study: 29352578

Group type: EXPERIMENTAL
Intervention: Physiotherapist-led group exercise and education program for preventing recurrence of low back pain (LBP) over 8 weeks.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 12
Study: 26821532

Group type: EXPERIMENTAL
Intervention: ISTp‐AL
Number of subjects: 988

Group type: COMPARATOR
Intervention: IPTp‐SP
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Placental malaria
Number of subjects: 988

Group type: COMPARATOR
Intervention: No placental malaria
Number of subjects: 988
Study: 23521782

Group type: EXPERIMENTAL
Intervention: Reflectance spectrophotometry measurements
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional finger-press test
Number of subjects: 78
Study: 23327695

Group type: EXPERIMENTAL
Intervention: Large dose of continuous veno-venous hemodiafiltration (CVVHDF) (70 ml×kg(‐1)×h(‐1), n = 9)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Moderate dose of CVVHDF (45 ml×kg(‐1)×h(‐1), n = 8)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Low dose of CVVHDF (25 ml×kg(‐1)×h(‐1), n = 11)
Number of subjects: 28
Study: 20026597

Group type: EXPERIMENTAL
Intervention: 15 microg dose of monovalent, unadjuvanted 2009 influenza A(H1N1) vaccine
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: 30 microg dose of monovalent, unadjuvanted 2009 influenza A(H1N1) vaccine
Number of subjects: 370
Study: 18836047

Group type: EXPERIMENTAL
Intervention: Soft hip protectors
Number of subjects: 1236

Group type: EXPERIMENTAL
Intervention: Hard hip protectors
Number of subjects: 1236

Group type: COMPARATOR
Intervention: Unprotected falls
Number of subjects: 1236
Study: 15877214

Group type: EXPERIMENTAL
Intervention: Stereotactic radiation therapy
Number of subjects: 0
Study: 12945073

Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin (30 mg mupirocin calcium hydrate ointment topically to each nostril three times a day for 3 days before operation)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Control (no mupirocin treatment)
Number of subjects: 395
Study: 11220448

Group type: EXPERIMENTAL
Intervention: BAS-mediated mechanism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BIS-mediated mechanism
Number of subjects: 0
Study: 9368506

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (60 mg orally every 6 h)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 8248954

Group type: EXPERIMENTAL
Intervention: colestipol/niacin plus diet therapy
Number of subjects: 188

Group type: COMPARATOR
Intervention: placebo plus diet therapy
Number of subjects: 188
Study: 3795263

Group type: EXPERIMENTAL
Intervention: Social-influences resistance training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Social-influences resistance training and Health education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peer leaders and familiar media models
Number of subjects: 0
Study: 30183874

Group type: EXPERIMENTAL
Intervention: Board game as educational technology (intervention group)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 99
Study: 27754722

Group type: EXPERIMENTAL
Intervention: Resveratrol (1,500 mg p.o. daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 23790343

Group type: EXPERIMENTAL
Intervention: mini-midvastus approach (mMV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: mini-medial parapatellar approach (mMPP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: surgical outcomes
Number of subjects: 40
Study: 23014487

Group type: EXPERIMENTAL
Intervention: NaFeEDTA-fortified whole wheat flour (6 mg of Fe)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Control meal (unfortified)
Number of subjects: 401
Study: 20075323

Group type: EXPERIMENTAL
Intervention: Economic intervention (child savings accounts, workshops, mentorship)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control (traditional care and support services: counseling and school supplies)
Number of subjects: 260
Study: 18948800

Group type: EXPERIMENTAL
Intervention: Smoking cessation therapy with individual counseling and nicotine substitution starting 4 weeks before surgery and continuing 4 weeks postoperatively.
Number of subjects: 117

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Smoking cessation therapy (abstainers).
Number of subjects: 117
Study: 15781813

Group type: EXPERIMENTAL
Intervention: Laquinimod 0.3 mg
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Laquinimod 0.3 mg (subgroup with at least one active lesion at baseline)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 11813128

Group type: EXPERIMENTAL
Intervention: Fetal surgery for myelomeningocele
Number of subjects: 77
Study: 9778752

Group type: EXPERIMENTAL
Intervention: Combined cold-adapted influenza A (H3N2) and trivalent inactivated influenza vaccine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Inactivated vaccine alone
Number of subjects: 100
Study: 7880088

Group type: EXPERIMENTAL
Intervention: Meningococcal A and C polysaccharide vaccine
Number of subjects: 1168
Study: 3418730

Group type: EXPERIMENTAL
Intervention: Low-fat, high-carbohydrate diet (15% of calories as fat)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Balanced diet (36% of calories as fat)
Number of subjects: 295
Study: 2008283

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 0.06 meq/ml sodium bicarbonate (LPH)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 2% lidocaine (L)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine (LE)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine and 0.06 meq/ml sodium bicarbonate (LEPH)
Number of subjects: 80
Study: 205828

Group type: EXPERIMENTAL
Intervention: p-aminosalicylic acid (PAS) 150 mg/kg/day
Number of subjects: 20
Study: 30053572

Group type: EXPERIMENTAL
Intervention: Antidepressant consumption
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Bipolar disorders (vs. schizophrenia)
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Higher MCSI psychotic score
Number of subjects: 655
Study: 27651513

Group type: COMPARATOR
Intervention: Simple Continuous Infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent Boluses
Number of subjects: 0
Study: 25595234

Group type: EXPERIMENTAL
Intervention: Bolt-on dimensions for vision problems, hearing problems, and tiredness
Number of subjects: 300

Group type: COMPARATOR
Intervention: Core EQ-5D states without bolt-on dimensions
Number of subjects: 300
Study: 23250000

Group type: EXPERIMENTAL
Intervention: Standard obesity rehabilitation plus combined planning and telephone aftercare intervention (6 phone calls for 6 months)
Number of subjects: 467

Group type: COMPARATOR
Intervention: Standard obesity rehabilitation
Number of subjects: 467
Study: 21168113

Group type: EXPERIMENTAL
Intervention: Aroma massage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plain massage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 19720635

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 1507
Study: 17556604

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Chloroquine + Pyrimethamine (CQ + P)
Number of subjects: 500
Study: 27118470

Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg loading dose followed by 75 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All treatments (Aspirin 300 mg, Aspirin 75 mg, Clopidogrel)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study: 11879344

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 242

Group type: COMPARATOR
Intervention: Nonsurgical treatment
Number of subjects: 242
Study: 9444449

Group type: EXPERIMENTAL
Intervention: Insulin lispro in combination with NPH human insulin administered twice daily
Number of subjects: 707

Group type: COMPARATOR
Intervention: Regular human insulin in combination with NPH human insulin administered twice daily
Number of subjects: 707
Study: 7944443

Group type: EXPERIMENTAL
Intervention: Hepatectomy
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Hepatectomy and coagulation therapy for remaining tumor
Number of subjects: 21

Group type: COMPARATOR
Intervention: Coagulation therapy only
Number of subjects: 21
Study: 3555566

Group type: EXPERIMENTAL
Intervention: Combination treatment (verapamil 120 mg three times a day and atenolol 100 mg once a day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg three times a day
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg once a day
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31846169

Group type: EXPERIMENTAL
Intervention: Ultrasonic activation of intracanal‐heated NaOCl (group B)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ultrasonic activation (group A)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Syringe-and-needle irrigation (group C)
Number of subjects: 18
Study: 30300557

Group type: EXPERIMENTAL
Intervention: S/F Easyhaler
Number of subjects: 227

Group type: COMPARATOR
Intervention: Seretide Diskus
Number of subjects: 227
Study: 28780395

Group type: EXPERIMENTAL
Intervention: PARO (robotic seal)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Plush toy
Number of subjects: 415

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 415
Study: 26255172

Group type: EXPERIMENTAL
Intervention: Stepping Stones Triple P (SSTP) plus Acceptance and Commitment Therapy (ACT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Care-as-usual (CAU)
Number of subjects: 59
Study: 23954534

Group type: EXPERIMENTAL
Intervention: Steroids with prompt delivery (PD group) after 48 hours
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Steroids and expectant management (EXM group)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Steroids with prompt delivery (PD group)
Number of subjects: 267
Study: 21367563

Group type: EXPERIMENTAL
Intervention: Infraclavicular brachial plexus block (IB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Local infiltration anesthesia (C)
Number of subjects: 60
Study: 18799288

Group type: EXPERIMENTAL
Intervention: d-cycloserine 50 mg once-weekly
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 16537563

Group type: EXPERIMENTAL
Intervention: Cetrorelix with OC pretreatment
Number of subjects: 182

Group type: COMPARATOR
Intervention: Buserelin
Number of subjects: 182
Study: 12660671

Group type: EXPERIMENTAL
Intervention: Duke Treadmill Score (DTS)
Number of subjects: 6251

Group type: EXPERIMENTAL
Intervention: Veteran Affairs Medical Center Score (VAMCS)
Number of subjects: 6251

Group type: EXPERIMENTAL
Intervention: GISSI-2 Index
Number of subjects: 6251
Study: 11591552

Group type: EXPERIMENTAL
Intervention: Symptom-limited stair climbing
Number of subjects: 83
Study: 9390483

Group type: EXPERIMENTAL
Intervention: Early tracheostomy (days 3-5)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Late tracheostomy (days 10-14)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Continued endotracheal intubation
Number of subjects: 157
Study: 7946102

Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine once every month
Number of subjects: 121

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine
Number of subjects: 121
Study: 2895374

Group type: EXPERIMENTAL
Intervention: Physicians examining patients with respiratory signs
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Presence or absence of respiratory signs
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Differing from majority on signs
Number of subjects: 24
Study: 29606011

Group type: EXPERIMENTAL
Intervention: Healthy Beat Acupunch (HBA) regimen, 40-min session, 3 times per week for 6 months
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 228
Study: 31340542

Group type: EXPERIMENTAL
Intervention: IoT-based monitoring using a Wireless Sensor Kit for behavioral aspects (bed/rest patterns, toilet usage, room presence)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regression framework for detecting trends and labeling anomalies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cloud-based analytics services for automatic extraction of relevant information from raw sensor data streams
Number of subjects: 0
Study: 28100438

Group type: EXPERIMENTAL
Intervention: 35 mg/kg rifampicin per day with isoniazid, pyrazinamide, and ethambutol
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: 10 mg/kg rifampicin per day with isoniazid, pyrazinamide, and SQ109
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: 20 mg/kg rifampicin per day with isoniazid, pyrazinamide, and SQ109
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: 10 mg/kg rifampicin per day with isoniazid, pyrazinamide, and moxifloxacin
Number of subjects: 365

Group type: COMPARATOR
Intervention: Control regimen (10 mg/kg rifampicin, 5 mg/kg isoniazid, 25 mg/kg pyrazinamide, and 15-20 mg/kg ethambutol)
Number of subjects: 365
Study: 25403587

Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (600 mg fixed dose)
Number of subjects: 596

Group type: COMPARATOR
Intervention: Intravenous trastuzumab (weight-based)
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Both subcutaneous and intravenous trastuzumab
Number of subjects: 596
Study: 23234805

Group type: EXPERIMENTAL
Intervention: Zibotentan 10mg/day plus carboplatin and paclitaxel
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo plus carboplatin and paclitaxel
Number of subjects: 120
Study: 21813840

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of diethylcarbamazine and albendazole (DEC/ALB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Albendazole (ALB)
Number of subjects: 0
Study: 19076157

Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg at 22.00 h every night
Number of subjects: 20
Study: 16673379

Group type: EXPERIMENTAL
Intervention: Transurethral radiofrequency energy (RF) collagen micro-remodeling
Number of subjects: 173

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 173
Study: 15112170

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC), 400 mg, thrice daily the day before and day of the contrast procedure
Number of subjects: 91

Group type: COMPARATOR
Intervention: No drug (control group)
Number of subjects: 91
Study: 10782553

Group type: EXPERIMENTAL
Intervention: Coping-orientated group therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Supportive therapy group
Number of subjects: 32
Study: 9133220

Group type: EXPERIMENTAL
Intervention: Oral clonidine test
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Oral guanfacine test
Number of subjects: 17
Study: 1404350

Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted relaxation for 4 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study: 4027785

Group type: EXPERIMENTAL
Intervention: Standard techniques for graft handling
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Changing gloves before preclotting the graft
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Established graft infection
Number of subjects: 77
Study: 31547214

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 63

Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 63